Maria I Carlo1, Joshua Chaim2, Sujata Patil3, Yelena Kemel4, Alison M Schram1, Kaitlin Woo3, Devyn Coskey1, Gouri J Nanjangud5, Martin H Voss1, Darren R Feldman1, James J Hsieh6, A Ari Hakimi7, Ying-Bei Chen5, Robert J Motzer1, Chung-Han Lee8. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Epidemiology/Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY. 7. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 8. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: leec4@mskcc.org.
Abstract
BACKGROUND: Renal medullary carcinoma (RMC) is a rare and aggressive type of kidney cancer that primarily affects young adults with sickle cell trait; outcomes are poor despite treatment. Identifying molecular features of this tumor could provide biologic rationale for novel targeted therapies. The objective was to report on clinical outcomes with systemic therapy and characterize molecular features. PATIENTS AND METHODS: This was a retrospective analysis on 36 patients given a pathologic diagnosis of RMC at one institution from 1995 to 2015. Tumors were analyzed for expression of SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1 (SMARCB1) through immunohistochemistry and for genomic alterations with fluorescence in situ hybridization for SMARCB1, and targeted next-generation sequencing. Time from initiation of therapy to progression of disease and overall survival were calculated using the Kaplan-Meier method. RESULTS: The median age in the cohort was 28 (range, 12-72) years, and all patients tested had sickle cell trait. Overall survival was 5.8 months (95% confidence interval [CI], 4.1-10.9) and for 12 patients who received platinum-based therapy, median progression-free survival was 2.5 months (95% CI, 1.2-not reached). A total of 10 available tumors underwent analysis with fluorescence in situ hybridization for SMARCB1; this revealed loss of heterozygosity with concurrent translocation in 8, and biallelic loss in 2. Next-generation targeted sequencing showed no recurring mutations. CONCLUSIONS: Outcome was generally poor in this cohort of patients with RMC. Uniform loss of SMARCB1 is a key molecular feature in this tumor and mechanism of loss appears to be mostly through translocations and deletions.
BACKGROUND:Renal medullary carcinoma (RMC) is a rare and aggressive type of kidney cancer that primarily affects young adults with sickle cell trait; outcomes are poor despite treatment. Identifying molecular features of this tumor could provide biologic rationale for novel targeted therapies. The objective was to report on clinical outcomes with systemic therapy and characterize molecular features. PATIENTS AND METHODS: This was a retrospective analysis on 36 patients given a pathologic diagnosis of RMC at one institution from 1995 to 2015. Tumors were analyzed for expression of SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1 (SMARCB1) through immunohistochemistry and for genomic alterations with fluorescence in situ hybridization for SMARCB1, and targeted next-generation sequencing. Time from initiation of therapy to progression of disease and overall survival were calculated using the Kaplan-Meier method. RESULTS: The median age in the cohort was 28 (range, 12-72) years, and all patients tested had sickle cell trait. Overall survival was 5.8 months (95% confidence interval [CI], 4.1-10.9) and for 12 patients who received platinum-based therapy, median progression-free survival was 2.5 months (95% CI, 1.2-not reached). A total of 10 available tumors underwent analysis with fluorescence in situ hybridization for SMARCB1; this revealed loss of heterozygosity with concurrent translocation in 8, and biallelic loss in 2. Next-generation targeted sequencing showed no recurring mutations. CONCLUSIONS: Outcome was generally poor in this cohort of patients with RMC. Uniform loss of SMARCB1 is a key molecular feature in this tumor and mechanism of loss appears to be mostly through translocations and deletions.
Authors: Sarah K Knutson; Satoshi Kawano; Yukinori Minoshima; Natalie M Warholic; Kuan-Chun Huang; Yonghong Xiao; Tadashi Kadowaki; Mai Uesugi; Galina Kuznetsov; Namita Kumar; Tim J Wigle; Christine R Klaus; Christina J Allain; Alejandra Raimondi; Nigel J Waters; Jesse J Smith; Margaret Porter-Scott; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Toshimitsu Uenaka; Roy M Pollock; Kevin W Kuntz; Akira Yokoi; Heike Keilhack Journal: Mol Cancer Ther Date: 2014-02-21 Impact factor: 6.261
Authors: Mahul B Amin; Steven C Smith; Abbas Agaimy; Pedram Argani; Eva Marie Compérat; Brett Delahunt; Jonathan I Epstein; John N Eble; David J Grignon; Arndt Hartmann; Ondřej Hes; Michelle S Hirsch; Rafael E Jimenez; Lakshmi P Kunju; Guido Martignoni; Jesse K McKenney; Holger Moch; Rodolfo Montironi; Gladell P Paner; Priya Rao; John R Srigley; Satish K Tickoo; Victor E Reuter Journal: Am J Surg Pathol Date: 2014-07 Impact factor: 6.394
Authors: Sumanta K Pal; Toni K Choueiri; Kai Wang; Depinder Khaira; Jose A Karam; Eliezer Van Allen; Norma A Palma; Mark N Stein; Adrienne Johnson; Rachel Squillace; Julia A Elvin; Juliann Chmielecki; Roman Yelensky; Evgeny Yakirevich; Doron Lipson; Douglas I Lin; Vincent A Miller; Philip J Stephens; Siraj M Ali; Jeffrey S Ross Journal: Eur Urol Date: 2015-07-03 Impact factor: 20.096
Authors: Sarah K Knutson; Natalie M Warholic; Tim J Wigle; Christine R Klaus; Christina J Allain; Alejandra Raimondi; Margaret Porter Scott; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock; Kevin W Kuntz; Heike Keilhack Journal: Proc Natl Acad Sci U S A Date: 2013-04-25 Impact factor: 11.205
Authors: A Ari Hakimi; Phillip T Koi; Paul M Milhoua; Netta M Blitman; Maomi Li; Vladimir Hugec; Janice P Dutcher; Reza Ghavamian Journal: Urology Date: 2007-11 Impact factor: 2.649
Authors: I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre Journal: Nature Date: 1998-07-09 Impact factor: 49.962
Authors: David S Tourigny; Mark Zucker; Minsoo Kim; Paul Russo; Jonathan Coleman; Chung-Han Lee; Maria I Carlo; Ying-Bei Chen; A Ari Hakimi; Ritesh R Kotecha; Ed Reznik Journal: Front Oncol Date: 2022-06-28 Impact factor: 5.738
Authors: Elzbieta Sarnowska; Michal Szymanski; Nataliia Rusetska; Marcin Ligaj; Iga Jancewicz; Pawel Cwiek; Marta Skrodzka; Marcin Leszczynski; Joanna Szarkowska; Alicja Chrzan; Malgorzata Stachowiak; Jaroslaw Steciuk; Anna Maassen; Lech Galek; Tomasz Demkow; Janusz A Siedlecki; Tomasz J Sarnowski Journal: Am J Cancer Res Date: 2017-11-01 Impact factor: 6.166
Authors: Pavlos Msaouel; Andrew L Hong; Elizabeth A Mullen; Michael B Atkins; Cheryl Lyn Walker; Chung-Han Lee; Marcus A Carden; Giannicola Genovese; W Marston Linehan; Priya Rao; Maria J Merino; Howard Grodman; Jeffrey S Dome; Conrad V Fernandez; James I Geller; Andrea B Apolo; Najat C Daw; H Courtney Hodges; Marva Moxey-Mims; Darmood Wei; Donald P Bottaro; Michael Staehler; Jose A Karam; W Kimryn Rathmell; Nizar M Tannir Journal: Clin Genitourin Cancer Date: 2018-09-12 Impact factor: 2.872
Authors: Andrew L Hong; Yuen-Yi Tseng; Jeremiah A Wala; Won-Jun Kim; Bryan D Kynnap; Mihir B Doshi; Guillaume Kugener; Gabriel J Sandoval; Thomas P Howard; Ji Li; Xiaoping Yang; Michelle Tillgren; Mahmhoud Ghandi; Abeer Sayeed; Rebecca Deasy; Abigail Ward; Brian McSteen; Katherine M Labella; Paula Keskula; Adam Tracy; Cora Connor; Catherine M Clinton; Alanna J Church; Brian D Crompton; Katherine A Janeway; Barbara Van Hare; David Sandak; Ole Gjoerup; Pratiti Bandopadhayay; Paul A Clemons; Stuart L Schreiber; David E Root; Prafulla C Gokhale; Susan N Chi; Elizabeth A Mullen; Charles Wm Roberts; Cigall Kadoch; Rameen Beroukhim; Keith L Ligon; Jesse S Boehm; William C Hahn Journal: Elife Date: 2019-03-12 Impact factor: 8.140
Authors: Liwei Jia; Maria I Carlo; Hina Khan; Gouri J Nanjangud; Satshil Rana; Robert Cimera; Yanming Zhang; A Ari Hakimi; Amit K Verma; Hikmat A Al-Ahmadie; Samson W Fine; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; Victor E Reuter; Benjamin A Gartrell; Ying-Bei Chen Journal: Mod Pathol Date: 2019-04-12 Impact factor: 7.842
Authors: Pavlos Msaouel; Gabriel G Malouf; Xiaoping Su; Hui Yao; Durga N Tripathi; Melinda Soeung; Jianjun Gao; Priya Rao; Cristian Coarfa; Chad J Creighton; Jean-Philippe Bertocchio; Selvi Kunnimalaiyaan; Asha S Multani; Jorge Blando; Rong He; Daniel D Shapiro; Luigi Perelli; Sanjana Srinivasan; Federica Carbone; Patrick G Pilié; Menuka Karki; Riyad N H Seervai; Bujamin H Vokshi; Dolores Lopez-Terrada; Emily H Cheng; Ximing Tang; Wei Lu; Ignacio I Wistuba; Timothy C Thompson; Irwin Davidson; Virginia Giuliani; Katharina Schlacher; Alessandro Carugo; Timothy P Heffernan; Padmanee Sharma; Jose A Karam; Christopher G Wood; Cheryl L Walker; Giannicola Genovese; Nizar M Tannir Journal: Cancer Cell Date: 2020-04-30 Impact factor: 31.743
Authors: William C Hahn; Matthew Meyerson; Andrew L Hong; Kar-Tong Tan; Hyunji Kim; Jian Carrot-Zhang; Yuxiang Zhang; Won Jun Kim; Guillaume Kugener; Jeremiah A Wala; Thomas P Howard; Yueh-Yun Chi; Rameen Beroukhim; Heng Li; Gavin Ha; Seth L Alper; Elizabeth J Perlman; Elizabeth A Mullen Journal: Genome Med Date: 2021-07-14 Impact factor: 11.117